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Although morphine is frequently administered to treat proce-
dural pain in neonates and young children, little is known about 
the effects of this drug on developing neural circuitry during the 
brain growth spurt. Here we systematically explored the impact 
of morphine on neuronal survival and differentiation during the 
peak synaptogenic period. By focusing on the rat medial prefron-
tal cortex, we show that single bolus ip injections of morphine, 
although it induces deep sedation and analgesia, do not entrain 
apoptosis in this cortical region either at postnatal day 7 or at post-
natal day 15. Iontophoretic single cell injections of Lucifer Yellow 
followed by semiautomatic neuronal arbor tracing revealed that 
repeated daily administration of this drug between postnatal days 
7 and 15 or 15 and 20 did not interfere with dendritic development 
of layer 5 pyramidal neurons. Confocal microscopic analysis of 
dendritic spines at the aforementioned distinct stages of the brain 
growth spurt demonstrated that neither single bolus nor repeated 
administration of morphine affected the density of these postsyn-
aptic structures. Altogether, these preclinical rodent experimental 
observations argue against overt neurotoxic effects of morphine 
exposure during the brain growth spurt.
Key Words:  apoptosis; brain; development; dendrite; mor-
phine; synapse.
The opioid analgesic morphine is one of the most commonly 
prescribed pharmacological agents to treat postoperative pain in 
children (Duedahl and Hansen, 2007; Tesler et al., 1994). This 
drug produces analgesia both at the spinal and at the supraspi-
nal level through activation of the mu type opioid receptors 
(Jensen, 1997; Milligan, 2005; Yaksh, 1997). The molecular 
mechanisms underlying these powerful clinical effects involve 
the activation of G-protein-activated inwardly rectifying potas-
sium channels together with G
o
 protein-coupled inhibition of 
voltage-gated calcium channels and of the adenylate cyclase 
signaling cascade (carter and Medzihradsky, 1993; ikeda et al., 
2000; Minami and satoh, 1995; Piros et al., 1995). Following 
morphine-induced activation of the mu receptor, the over-
all impact of these signaling pathways on neural circuitry is 
decreased neurotransmitter release, and thus, altered excitabil-
ity (schoffelmeer et al., 1992).
Neural activity plays a pivotal role in the formation of the 
central nervous system (chen and Ghosh, 2005; Hensch, 
2004). in this context, morphine-induced pharmacological 
interference with neurotransmitter release could markedly 
impair physiological activity patterns in the developing brain. 
This, in turn, may result in altered circuitry assembly, and 
thereby information processing in the central nervous system. 
in line with this possibility, experimental evidence indicates 
that maternal administration of morphine during pregnancy 
leads to a significant reduction in neuronal packing density 
and cortical thickness in offspring (sadraie et al., 2008; seatriz 
and Hammer, 1993), which is correlated with altered sensory-
motor processing and learning abilities in these animals (Zagon 
et al., 1979a,b). Most importantly, human data also suggest a 
causal link between in utero exposure to opiates and adverse 
neurodevelopmental outcome (reviewed in Hunt et al., 2008; 
Lester and Lagasse, 2010).
Although the impact of chronic maternal opioid exposure 
on in utero brain development has been widely studied, less 
is known about the effects of these drugs when administered 
during the brain growth spurt. This period of intense neur-
onal differentiation and synaptic development, during which 
millions of human infants are exposed to opioids every year 
worldwide in the context of perioperative or procedural pain 
management, extends from the last trimester of pregnancy up to 
the first few years of postnatal life in humans (Huttenlocher and 
Dabholkar, 1997). in rodents, in contrast, it is limited to a time 
window between the second and fourth postnatal weeks (De 
Felipe et al., 1997). Developing neural networks are particu-
larly sensitive to external stimuli during the brain growth spurt, 
and we have recently shown that anesthetics-induced interfer-
ence with physiological patterns of neurotransmission during 
this period can rapidly and lastingly modify neuronal architec-
ture (Briner et al., 2010, 2011; De Roo et al., 2009). Given the 
aforementioned effects of opioids on neurotransmitter systems, 
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the present study aimed to investigate the impact of morphine 
administration on neuronal survival, differentiation, and synap-
togenesis during the brain growth spurt in vivo by focusing on 
the rat medial prefrontal cortex (mPFc).
MATERIALS AND METHODS
The experimental protocol was conducted according to the guidelines of 
the swiss Federal Veterinary Office and was approved by the cantonal Animal 
Welfare committee. Wistar rats (charles River, Arbresle, France) were housed 
and bred in the animal facilities under a 12-h light/dark cycle and temperature-
controlled (22°c ± 2°c) conditions. Food and water were available ad libitum. 
Every effort was made to minimize the number of animals used and their suf-
fering. seven- to twenty-day-old pups were used according to the experimental 
settings. Each treatment group had a balanced number of pups from each dam, 
and both newborn male and female pups were used in this study.
Drug administration. Morphine (sintetica, Mendrisio, switzerland) was 
ip administered at concentrations of 1 or 10 mg/kg according to the experi-
mental protocol. in the control groups, animals received ip injections of 
physiological saline at equivalent volumes. Propofol was ip administered at a 
concentration of 50 mg/kg. Because morphine administration rapidly induced 
important sedation, both control and drug-treated rat pups were separated from 
their mothers and kept in individual cages on a heating pad to maintain body 
temperature at 37°c ± 0.5°c for up to 4 h postinjection. in experiments where 
repeated daily administration of morphine was performed, animals were then 
replaced with their mothers following this period. in a separate set of experi-
ments, we determined the effect of morphine on respiratory frequency and 
blood gas values. in these animals, morphine-induced analgesia permitted 
trans-thoracic puncture of the right atrium without any signs of suffering of 
the pups. Blood gas sample analyses were done with i-sTAT analyzer (Abbott 
AG, Baar, switzerland) and blood glucose with Bayer Ascensia contour (Bayer 
Health care, Tarrytown, NY).
Activated caspase-3 immunohistochemistry. Four hours following ip 
injections of physiological saline (control), morphine (10 mg/kg) or propofol 
(50 mg/kg) on PND 7 or PND 15, rat pups received a lethal dose of pentobarb-
ital (100 mg/kg ip) and were perfused transcardially with a 4% paraformalde-
hyde solution. Brains were then removed, postfixed overnight, and subsequently 
dehydrated through a serial passage with increasing sucrose concentrations 
(10, 20, and 30%) at 4°c. Twenty-micrometer-thick coronal sections contain-
ing the prefrontal cortical region were then obtained using a cryostate (Leica, 
Leipzig, Germany). sections were washed in PBs, preincubated 30 min in a 
1% Triton, and incubated overnight with an antibody recognizing the activated 
(cleaved) form of caspase-3 (1:500; cell signaling, Beverly, MA). sections 
were then rinsed in PBs, incubated overnight with an Alexa-conjugated sec-
ondary antibody (1:1000; Molecular Probes, carlsbad, cA), and mounted and 
coverslipped using immunomount (Thermo scientific, Pittsburgh, PA).
Iontophoretic post hoc single cell injections. Animals were sacrificed at 
defined time points by an ip overdose of pentobarbital (100 mg/kg) and per-
fused transcardially with a 4% paraformaldehyde and 0.125% glutaraldehyde 
solution (pH 7.4). Brains were then removed and postfixed for 2 h in 4% para-
formaldehyde. Three-hundred-micrometer–thick coronal sections were then 
cut on a vibratome in ice-cold PBs (pH 7.4). coronal sections were prestained 
for 30 min with methylene blue, which enables the visualization of neuronal 
somata, mounted into an injection chamber, and placed on the fixed stage of a 
Zeiss microscope equipped with a micromanipulator. Layer 5 pyramidal neu-
rons were loaded iontophoretically with a 5% Lucifer Yellow solution (sigma 
Aldrich, st Louis, MO), using sharp micropipettes with a negative current of 70 
nA. Loading time per cell was 4 min, and 6–9 cells were injected per slice; we 
used two slices per animal and three animals per experimental group. To reveal 
Lucifer Yellow injected neurons, brain sections were incubated 48 h with an 
anti-Lucifer-Yellow antibody (1:5000; sigma Aldrich, schnelldorf, Germany) 
at room temperature in a PBs solution containing sucrose (5%), bovine serum 
albumin (2%), Triton (1%), and azide (0.1%). slices were washed thrice for 
20 min in PBs and incubated with an Alexa-conjugated secondary antibody 
(1:1000; Molecular Probes) for 48 h. slices were then mounted and cover-
slipped using immunomount (Thermo scientific).
Analysis of neuronal cytoarchitecture. Only pyramidal neurons lying 
within layer 5 of the mPFc with proper filling of distal dendritic tips were 
included into the analysis. Reconstruction of the three-dimensional basal 
 dendritic arbor structure was performed using a computer-based Neurolucida 
system (Microbrightfield, Williston, VT) with a 40× objective on a Nikon 
microscope (Nikon corporation, Tokyo, Japan). in each experimental group, 
total dendritic length, number of branching points, and sholl’s distribution 
for both basal dendritic arbors were quantified by an observer blind to the 
experimental conditions. An LsM 510 meta confocal microscope (carl Zeiss, 
Göttingen, Germany) equipped with a 63× oil-immersion objective was used 
for dendritic spine analysis. spine analysis was performed on acquired stacks 
of images using a homemade plug-in written for Osirix software (Pixmeo, 
Geneva, switzerland). This plug-in allows precise spine quantification, indi-
vidual tagging, and measurement in three dimensions by scrolling through the 
z-axis. We defined spines as structures emerging from the dendrites that were 
longer than 0.4 µm and for which we could distinguish an enlargement at the 
tip (spine head). spine head diameters were measured at their largest width 
in xy-axis on the z-image corresponding to the central axis of the spine head.
Note that for illustration purposes, images presented in figures are maxi-
mum intensity projections of z stacks with volume rendering, further treated 
with a Gaussian blur filter.
Statistics. All statistics are presented as the mean ± sD. Normality was 
tested for each distribution (D’Agostino and Pearson test), and α was set to 
5% for all tests. For multiple comparisons, statistical significance was deter-
mined using one-way ANOVA followed by Bonferroni’s post hoc tests (Prism 
software version 5.0a, GraphPad inc., La Jolla, cA). Where appropriate, two-
tailed student’s t-test was performed. p < 0.05 was considered as statistically 
significant.
RESULTS
Effect of Morphine Administration on Physiological 
Parameters
in previous experimental studies, evaluating the effects of 
morphine on brain development, the maximum ip-administered 
dose of this drug was 10 mg/kg. Because one important side 
effect of morphine administration is mu receptor–mediated 
respiratory depression, in a first set of experiments we evaluated 
how this dosing regimen affects physiological parameters. To 
this aim, we focused on two distinct developmental time points 
of the brain growth spurt: postnatal days 7 and 15. single-dose 
morphine (10 mg/kg) administration at these stages induced the 
loss of the righting reflex within 30 min, an effect that persisted 
up to 90 min postinjection. Also, this dosing regimen induced 
profound analgesia for at least 6 h when evaluated with the 
tail clamp test. Respiratory monitoring following single-dose 
ip administration of 10 mg/kg morphine revealed a highly 
significant depression of respiratory frequency in the two age 
groups when evaluated 30 min following injection (PND 7: 
−63 ± 10%, from 153 ± 15 to 57 ± 16 breaths/min, p < 0.0001; 
PND 15: −45 ± 12%, from 173 ± 19 to 95 ± 20 breaths/min, 
p  <  0.0001) (Fig.  1). in 7-day-old animals, this respiratory 
depression persisted up to 120 min following morphine injection 
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and normalized when assessed at 6 h postadministration. in 
contrast, respiratory frequency was comparable with control 
values 120 min following morphine exposure in 15-day-old 
pups (Fig.  1). Blood gas sampling at defined time intervals 
following morphine administration revealed that the observed 
respiratory depression was accompanied with mild respiratory 
acidosis in both age groups (Table 1).
single-dose morphine (10 mg/kg) administration does not 
induce apoptosis in the prefrontal and somatosensory cortices 
during the brain growth spurt.
A large number of drugs that interfere with physiological pat-
terns of neurotransmission, including general anesthetics, have 
been shown to induce developmental stage-dependent apop-
tosis when administered during the brain growth spurt (Loepke 
and soriano, 2008). To our knowledge, no such data in the lit-
erature is available regarding morphine exposure. Thus, in a 
next series of experiments, a single dose of 10 mg/kg morphine 
was ip administered to rat pups at PND 7 or at PND 15, and 
the effect of this treatment paradigm on apoptosis in the mPFc 
was evaluated 4 h postinjection using an antibody against the 
cleaved (i.e., activated) form of caspase-3. As seen in Figure 2, 
the number of cleaved caspase-3 positive cells was comparable 
between control and morphine-exposed pups either at PND 7 
or at PND 15. As a positive control to define specificity of these 
findings, we exposed pups from the same litters to propofol 
(50 mg/kg ip) because this drug has been previously demon-
strated to rapidly induce neuroapoptosis in the developing brain 
at PND 7 (cattano et al., 2008). in line with these observations, 
we also found that propofol rapidly induced highly significant 
(p = 0.0002) increase in the number of cleaved caspase-3 posi-
tive cells in the mPFc at PND 7 but not at PND 15 (Fig. 2). To 
assess the effect of morphine exposure on neuronal cell death 
in other cortical regions, we also evaluated neuroapoptosis in 
the somatosensory cortex of PND 7 and PND 15 animals. As 
seen in Figure 2, although the extent of naturally occurring cell 
death at PND 7 in this cortical region is higher than that in 
the mPFc, propofol but not morphine still induced significant 
cell death. Altogether, these data strongly suggest that single-
dose morphine exposure, despite the accompanying respiratory 
depression and mild respiratory acidosis, does not trigger apop-
tosis during the brain growth spurt.
Repeated Exposure to Morphine During the Brain Growth 
Spurt Does Not Impair Dendritic Arbor Differentiation
We have previously shown that dendritic arbor of layer 
5 pyramidal neurons in the mPFc undergoes marked 
differentiation during the early postnatal period (Briner et al., 
2011). Given that the most intense phase of arbor development 
during the brain growth spurt occurs around the second postnatal 
week (Juraska, 1982; Petit et al., 1988; Uylings et al., 1994), we 
thus investigated how exposure of rat pups to morphine during 
this period affects dendritic growths. To this end, rat pups 
received daily ip injections of morphine (either 1 or 10 mg/kg) 
from PND 7 to PND 15, and the effects of this treatment on 
basal dendritic arbor architecture of layer 5 pyramidal neurons 
in the mPFc was evaluated at PND 15. As seen in Figure 3, this 
experimental paradigm did not induce any significant changes 
in morphological parameters describing dendritic arborization 
pattern. Because ontogeny of mu receptor expression has been 
reported to be different between early and later stages of the 
brain growth spurt (Kent et al., 1981; Kornblum et al., 1987), 
we next explored the impact of morphine exposure on neuronal 
differentiation at later developmental stages by daily exposing 
young pups to this drug between PND 15 and PND 20. similar 
to exposure at earlier developmental stages, we found no effect 
of morphine on dendritic arbor development during this time 
period (Fig.  4). Altogether, these results strongly suggest 
that exposure to morphine during the brain growth spurt 
does not impair dendritic arbor development of these layer 5 
pyramidal cells.
FIG. 1. Effect of morphine administration on respiratory frequency. 
Morphine (10 mg/kg) was ip injected either on PND or on PND 15, and the 
effect of this treatment paradigm on respiratory frequency was monitored up 
to 360 min postinjection. Data are expressed as mean ± sD, n = 4–8 animals at 
each time point in each age group. One-way ANOVA with Bonferroni’s post 
hoc tests were used for searching statistical differences between time points in 
each age group. ***p < 0.001 compared with the initial respiratory frequency 
(i.e., at 0 min) in each age group.
TABLE 1
Physiological Data in 7- and 15-Day-Old Animals Following ip 
Single Bolus Administration of Morphine
pH PcO2 (kPA) Glucose (mg/dl)
PND 7 0 min 7.39 ± 0.04 6.63 ± 0.94 107 ± 13
30 min 7.22 ± 0.02 10.31 ± 0.45 180 ± 20
60 min 7.27 ± 0.1 10.02 ± 2.17 182 ± 32
120 min 7.22 ± 0.01 7.56 ± 1.60 66 ± 25
PND 15 0 min 7.38 ± 0.05 5.63 ± 1.22 76 ± 7
30 min 7.22 ± 0.02 9.61 ± 0.30 147 ± 6
60 min 7.23 ± 0.02 10.04 ± 0.44 136 ± 14
120 min 7.36 ± 0.02 7.89 ± 0.44 142 ± 8
Note. Data depict mean ± sD values of venous blood samples at distinct time 
points following morphine (10 mg/kg) administration. n = 3 animals per time 
points in each age groups.
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Effects of Morphine on Dendritic Spinogenesis During 
Development
Dendritic spines represent primary postsynaptic sites of 
excitatory synaptic inputs to pyramidal neurons, and it is now 
well established that studying densities and morphology of these 
structures provide us valuable information on morphofunctional 
characteristics of neural networks (Bhatt et al., 2009; Holtmaat 
and svoboda, 2009). in order to gain insights into the impact 
of morphine on dendritic spine development, we evaluated 
the effects of both acute and repeated exposures to this drug 
on dendritic spine development. Because we have previously 
shown that dendritic spines can undergo rapid, within hours, 
remodeling following drug exposure (Briner et al., 2010, 2011; 
De Roo et  al., 2009), PND 7 rat pups were ip injected with 
either 1 or 10 mg/kg morphine, and the effect of this treatment 
on dendritic spines of layer 5 pyramidal neurons in the mPFc 
was evaluated 4 h later. As seen in Figure  5, although single 
bolus propofol (40 mg/kg ip) rapidly decreased dendritic spine 
densities, single-dose morphine exposure affected neither 
dendritic spine densities nor their morphology, as evaluated by 
the analysis of spine head diameter, at this developmental stage. 
similar results were obtained following single-dose morphine 
exposure (1 and 10 mg/kg) at PND 15, where propofol increased 
spine densities (Fig. 6). Altogether, these data strongly suggest 
that single-dose morphine exposure does not impair, at least 
acutely, dendritic spines during the brain growth spurt.
We next analyzed the impact of chronic morphine exposure 
on dendritic spines using the aforementioned repeated drug 
exposure protocols between PND 7 and PND 15 and between 
PND 15 and PND 20. As seen in Figures 7 and 8, despite the par-
ticularly intense phase of spine development during these peri-
ods (Briner et al., 2011), neither of these paradigms impaired 
dendritic spine densities. Analysis of spine head diameters 
following the PND 7 to PND 15 exposure revealed a statisti-
cally significant increase in the percentage of spines present-
ing with smaller head diameters either with 1 or with 10 mg/kg 
morphine exposure, and this was paralleled with a significant 
reduction in the number of middle-size spines at either doses of 
this drug (Fig. 7D). in contrast, no such changes were observed 
in the PND 15 to PND 20 exposed animals (Fig. 8D).
DISCUSSION
The present study demonstrates that morphine exposure 
does not alter neuronal arbor differentiation and excitatory 
synaptogenesis of pyramidal neurons during the brain growth 
FIG. 2. Morphine does not induce caspase-3 activation in the cerebral cortex during the brain growth spurt. Rat pups received single ip injection of morphine 
(10 mg/kg) or propofol (50 mg/kg) either on PND 7 or on PND 15, and the number of cleaved caspase-3 positive cells in the mPFc (A, c) and in the somatosensory 
cortex (B, D) was evaluated 4 h post injection. Data are expressed as mean ± sD, n = 4 animals at each drug regimen in each age group. One-way ANOVA with 
Bonferroni’s post hoc tests was used for searching statistical differences between experimental conditions in each age group. ***p < 0.001 compared with the 
control, non-drug-exposed animals in each age group. ssc, somatosensory cortex.
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spurt. To our knowledge, these investigations provide the first in 
vivo data regarding the impact of this drug on morphofunctional 
parameters describing neuronal networks in the cerebral cortex 
during this intense phase of early postnatal development. We 
first show that single-dose morphine administration at two 
distinct stages of the brain growth spurt, although results in 
sedation, analgesia, and respiratory depression accompanied 
by mild respiratory acidosis, does not induce apoptosis in the 
cerebral cortex. By focusing on dendritic arbor development 
of layer 5 pyramidal neurons, we then demonstrate that 
repeated daily exposure to morphine during either the early or 
the later stages of the early postnatal period does not impair 
gross dendritic arbor development of these cells. Analysis of 
dendritic spines following single-dose morphine exposure 
using confocal microscopy reveals no effect of this drug on the 
structures representing postsynaptic sites of excitatory synaptic 
contacts on neurons. chronic administration of morphine 
during the early phase of the brain growth spurt results in 
an increase in the proportion of spines with smaller head 
diameters, whereas spine density remains unaltered. Finally, no 
effect of chronic morphine administration on dendritic spines 
was found when applied during later stages of the brain growth 
spurt. Altogether, these results are in agreement with and 
further extend recent preclinical observations arguing against 
potential neurotoxic effects of opioid exposure during the early 
postnatal period.
We investigated the effects of morphine exposure during 
the brain growth spurt. The rationale behind this choice was 
that although morphine is frequently administered during this 
period in human clinical practice (Duedahl and Hansen, 2007; 
Tesler et al., 1994), available knowledge on whether and how 
this drug may influence brain maturation at these developmen-
tal stages remains scarce. Opioid receptors, along with their 
endogenous peptide ligands, are present from early stages of 
development in peripheral organs and in the developing brain. 
in mice, transcripts of opioid receptors are detected in the gut 
epithelium as early as embryonic day 9.5 (E 9.5), while μ, κ, 
and δ receptor mRNAs are present in multiple brain regions 
from E 12 (Zhu et al., 1998). Regarding more specifically the 
development of the cerebral cortex, earlier ligand binding stud-
ies along with more recent works using in situ hybridization 
indicate important spatiotemporal differences in opioid recep-
tor ontogeny.
in rodents, μ opioid receptor mRNA can be detected as 
early as E 12 in the deep neuroepithelium of the cortical 
plate, and expression is also present later on in the developing 
cortical subplate (Tong et al., 2000; Zhu et al., 1998). in the 
rat neocortex, μ receptor transcripts are first detected at E16 
FIG. 3. Repeated daily administration of morphine does not impair dendritic growth during the early phase of the brain growth spurt. (A) Experimental 
protocol. (B) Representative Neurolucida reconstructions of Lucifer Yellow–injected pyramidal neurons in layer 5 of the mPFc on PND 15 from control and 
morphine-exposed animals. Quantitative analysis of (c) basal dendritic lengths, (D) branching points, and (E) sholl distribution in layer 5 pyramidal neurons from 
control and morphine-exposed animals. Data are expressed as mean ± sD, n = 4 animals at each drug regimen. One-way ANOVA with Bonferroni’s post hoc tests 
was used for searching statistical differences between experimental conditions. scale bar: 50 μm.
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with a predominance of expression in deep cortical layers 
(Tong et  al., 2000). μ receptor densities have been reported 
to decrease during the first few days of early postnatal life 
in rodents, and this period is then followed by a progressive 
several fold increase that reaches steady state around the end 
of the first postnatal month (Kent et al., 1981; Kornblum et al., 
1987; spain et al., 1985; Tong et al., 2000). Although further 
in vivo studies are needed to determine precise subcellular 
localization of μ receptors, in vitro observations using 
dissociated cortical cultures from newborn rodents indicate 
that these receptors are predominantly expressed on dendritic 
spines of pyramidal neurons (Liao et  al., 2005). δ opioid 
receptors are first detected in the rat telencephalon around E 
21; they are predominantly localized to cortical layer 2/3 and 5, 
and their distribution remains similar up to adult ages (Georges 
et al., 1998). κ receptor expression in the developing mouse 
cerebral cortex becomes detectable at E 17.5 (Zhu et al., 1998), 
but expression of this opioid receptor subtype in the postnatal 
cerebral cortex remains lower compared with that of μ and δ 
receptors (Georges et al., 1998).
Given the important socioeconomic impact of maternal drug 
abuse (Hunt et  al., 2008; Lester and Lagasse, 2010), a large 
number of experimental research studies targeted the impact of 
in utero opioid exposure on brain development. in this regard, 
early observations following prenatal exposure to methadone 
or morphine revealed decreased brain size and associated 
behavioral, cognitive, and motor deficits in offspring (seatriz 
and Hammer, 1993; Zagon and McLaughlin, 1977; Zagon 
et al., 1979a,b). More recent data further extend these obser-
vations by indicating impaired dendritic growth and synaptic 
plasticity in juvenile offspring of morphine-exposed pregnant 
rats (Mei et al., 2009; Niu et al., 2009). in contrast to stimu-
lation of opiod signaling pathways, naltrexone-induced block-
ade of opiate receptors in utero results in increased brain size, 
neurogenesis, and more elaborated neuronal arbor in newborn 
pups (Hauser et al., 1987; Reznikov et al., 1999; Zagon and 
McLaughlin, 1983).
To gain insights into how administration of morphine 
impacts on the developing cerebral cortex during the brain 
growth spurt, we primarily focused on layer 5 pyramidal 
neurons of the developing rat mPFc. in rodents, this brain 
region is considered as the functional equivalent of the human 
frontal cortex (Uylings et al., 2003), a cortical structure that is 
implicated in higher order cognitive and emotional functions 
FIG. 4. Repeated daily administration of morphine does not impair dendritic growth during the later phase of the brain growth spurt. (A) Experimental proto-
col. (B) Representative Neurolucida reconstructions of Lucifer Yellow–injected pyramidal neurons in layer 5 of the mPFc on PND 20 from control and morphine-
exposed animals. Quantitative analysis of (c) basal dendritic lengths, (D) branching points, and (E) sholl distribution in layer 5 pyramidal neurons from control 
and morphine-exposed animals. Data are expressed as mean ± sD, n = 4 animals at each drug regimen. One-way ANOVA with Bonferroni’s post hoc tests was 
used for searching statistical differences between experimental conditions. scale bar: 50 μm.
 MORPHiNE AND NEURONAL DEVELOPMENT 173
(Tsujimoto, 2008). importantly, considerable densities of 
opioid receptors have been reported in this cortical region of 
which layer 5 pyramidal neurons form the major output source 
(Adams, 2009; Kornblum et  al., 1987; Leriche et  al., 2007; 
Mansour et  al., 1987; Martin-schild et  al., 1999). Because 
the intense phase of neuronal differentiation and circuitry 
development spans over a time scale of weeks in rodents, 
we focused on two developmental time points, representing 
two functionally distinct period of the brain growth spurt, 
and explored the impact of morphine on neuronal survival, 
differentiation, and synaptogenesis. As an early stage, we chose 
the time point of PND 7 because this developmental period 
corresponds to the beginning of the brain growth spurt, when 
dendritic spine and synapse densities in the cerebral cortex are 
low (Briner et al., 2011; Juraska, 1982) and GABA
A
 receptor–
mediated neurotransmission is primarily excitatory due to high 
intracellular chloride concentrations (Blaesse et al., 2009). in 
contrast, synaptic density is several fold higher and actively 
ongoing on PND 15 (Briner et al., 2011; Juraska, 1982), and 
GABAergic signaling is already of inhibitory nature (Blaesse 
et al., 2009). Also, as discussed above, receptor binding and in 
situ hybridization studies indicate important differences in the 
temporal expression pattern of opioid receptor subtypes during 
the brain growth spurt (Kent et  al., 1981; Kornblum et  al., 
1987; spain et al., 1985; Tong et al., 2000). The ensemble of 
these observations thus strongly suggests that the sensitivity 
of developing neural systems to morphine exposure could 
be different at different stages of early postnatal life, raising 
thereby the need to target multiple time points in experimental 
studies.
We found that single bolus administration of morphine does 
not induce cell death in the prefrontal and somatosensory cortices 
at PND 7 and at PND 15. These results are in line with previous 
observations demonstrating that subcutaneous administration of 
a unique dose of morphine (10 mg/kg) on PND 3 did not induce 
apoptosis in rat pups (Black et al., 2008). in line, no apoptosis 
was detected in the spinal cord of rat pups following lumbar 
intrathecal injections of this drug in the early postnatal period 
(Westin et al., 2010). in fetal guinea pigs, at a developmental 
stage comparable with our and these aforementioned rodent 
studies, a 4-h-long iv infusion of the opioid fentanyl at high 
concentrations, aimed to maintain anesthesia, did not induce 
apoptosis (Rizzi et  al., 2008). Data from adult mice also 
suggest the lack of proapoptotic effect of morphine (Emeterio 
et al., 2006). Although these observations argue against short-
term morphine exposure–induced neurotoxicity, future work 
FIG. 5. single-dose morphine administration on PND 7 does not affect dendritic spine density and morphology. (A) Experimental protocol. (B) Representative 
volume rendering confocal reconstructions of dendritic shafts from control and morphine-exposed animals. (c) Quantitative analysis of dendritic spine densities 
on second-order basal dendritic shafts. (D) Frequency distribution histogram of spine head diameters in control and morphine-treated groups. Data are expressed 
as mean ± sD, n = 3 animals at each drug regimen. One-way ANOVA with Bonferroni’s post hoc tests was used for searching statistical differences between 
experimental conditions. A total of 1467 spines for controls, 1383 spines for the 1 mg/kg morphine group, 1448 spines for the 10 mg/kg morphine group, and 1349 
spines for the propofol (40 mg/kg) group were counted to determine spine density. scale bar: 4 μm.
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is needed to determine whether other cortical and subcortical 
regions, where opioid systems are also expressed, can be 
affected by morphine exposure during development. in this 
context, it is important to note that some subcortical regions, 
such as the mesostriatal system, express significantly higher 
amounts of opioid receptors than the cerebral cortex (Georges 
et al., 1998), and evaluating the impact of neonatal morphine 
exposure on the development of these brain regions should be 
thus of future interest. it is also important to underline that we 
found temporary respiratory depression and mild acidosis in 
animals following drug exposure, a condition that was often 
questioned to be a cause of increased neuroapoptosis following 
exposure to general anesthetics during the brain growth spurt 
(soriano et  al., 2005). Although in this study we cannot 
formally exclude that morphine protects against the potentially 
deleterious effects of transient respiratory depression in the 
developing brain, we believe that our data also suggest that 
transient mild respiratory acidosis per se does not induce 
apoptosis in the cerebral cortex in the early postnatal period.
One important focus of the present study was to investi-
gate how morphine impacts on the intense dendritic develop-
ment during the brain growth spurt. indeed, because the causal 
relationship between dendritic geometry and neuronal firing 
properties is well established (Hines and carnevale, 2001; van 
Ooyen et al., 2002), neuronal apoptosis is not the sole histologi-
cal parameter to be considered in evaluating potentially adverse 
drug effects on neuronal development. Earlier works reported 
morphine-induced impairment of dendritic arbor development 
when this drug was repeatedly administered in the pre- or peri-
natal period (Mei et  al., 2009; Ricalde and Hammer, 1990). 
chronic morphine administration was also found to decrease 
dendritic arbor complexity in the adult brain (Hu et al., 2008; Li 
et al., 2007). Results of our study, however, reveal that chronic 
morphine administration affects dendritic growth neither at 
early nor at later stages of the brain growth spurt, thereby posing 
additional arguments against potential neurotoxic effects of the 
drug during this period. The most plausible explanation of dis-
crepancies between our and the aforementioned results concern 
the differences in the developmental stage at which morphine 
was administered. Alternatively, this drug might have cortical 
layer–specific effects on pyramidal neurons. indeed, although 
we focused on layer 5 pyramidal neurons, emphasis has been 
placed on cortical layer 2/3 principal cells in those other studies. 
We cannot completely exclude potential technical confounders. 
FIG. 6. single-dose morphine administration on PND 15 does not affect dendritic spine density and morphology. (A) Experimental protocol. (B) Representative 
volume rendering confocal reconstructions of dendritic shafts from control and morphine-exposed animals. (c) Quantitative analysis of dendritic spine densities 
on second-order basal dendritic shafts. (D) Frequency distribution histogram of spine head diameters in control and morphine-treated groups. Data are expressed 
as mean ± sD, n = 3 animals at each drug regimen. One-way ANOVA with Bonferroni’s post hoc tests was used for searching statistical differences between 
experimental conditions. A total of 4123 spines for controls, 4889 spines for the 1 mg/kg morphine group, 5269 spines for the 10 mg/kg morphine group, and 6152 
spines for the propofol (40 mg/kg) group were counted to determine spine density. scale bar: 4 μm.
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Here, we used iontophoretic Lucifer Yellow single cell injec-
tions, a method that is generally considered as a gold standard 
to fully label neuronal arbor architecture. in contrast, Golgi-
stained randomly labeled neurons were analyzed by the other 
investigators mentioned herein. Finally, it is important to state 
that the fact that our results do not reveal a significant impact 
of morphine exposure on neuronal arbor does not obligatorily 
mean the absence of such an effect. indeed, our data represent 
results obtained from four animals (5 to 8 neurons analyzed 
per animal) in each experimental group. Power analysis reveals 
that the statistical power of these experiments remains under 
50% and at least 26 animals per experimental group would be 
needed to increase this power up to 80%. clearly, additional 
studies are needed to further investigate the effects of morphine 
on neuronal architecture.
in addition to spatial branching topology of dendritic arbor, 
microscopic surface irregularities, including dendritic spine 
density, shape, and distribution are also major determinants of 
neural responses (Arellano et al., 2007; schikorski and stevens, 
2001). Mu opioid receptors are expressed on dendritic spines 
(Liao et  al., 2005), and chronic administration of morphine 
in the perinatal period has been reported to decrease dendritic 
spine density (Ricalde and Hammer, 1990). More recent in 
vitro data demonstrate that this is mainly due to the decreased 
stabilization of newly formed spines, an effect mediated via 
the modulation of NeuroD activity (Liao et al., 2005; Zheng 
et al., 2010). Our data demonstrate that single-dose morphine 
administration does not impair dendritic spine density and 
morphology. Moreover, we found no effect on spine density 
when rat pups were repetitively exposed to this drug during 
either the early or the later stages of the peak synaptogenic 
period. These observations thus suggest a lack of effect of 
morphine on synaptogenesis during the brain growth spurt. 
Nevertheless, an important caveat to these results is that they 
represent post hoc observations. Because dendritic spines 
undergo intense turnover during the most intense phase of 
synaptogenesis (Holtmaat and svoboda, 2009; Lendvai et al., 
2000), we cannot this exclude that morphine affects the rate 
of this turnover, the formation, stabilization, or the elimination 
of spines. in fact, although we observed no change in spine 
densities following chronic exposure to morphine during the 
early phases of the brain growth spurt, analysis of dendritic 
FIG. 7. Effects of repeated daily administration of morphine during the early phase of the brain growth spurt on dendritic spine density and morphology. 
(A) Experimental protocol. (B) Representative volume rendering confocal reconstructions of dendritic shafts from control and morphine-exposed animals. (c) 
Quantitative analysis of dendritic spine densities on second-order basal dendritic shafts. (D) Frequency distribution histogram of spine head diameters in control 
and morphine-treated groups. Data are expressed as mean ± sD, n = 3 animals at each drug regimen. One-way ANOVA with Bonferroni’s post hoc tests was used 
for searching statistical differences between experimental conditions. A total of 4123 spines for controls, 4060 spines for the 1 mg/kg morphine group, and 3601 
spines for the 10 mg/kg morphine group were counted to determine spine density. scale bar: 4 μm; ***p < 0.001 compared with control group.
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spine head diameters revealed a significantly higher number 
of small spines in the morphine group compared with control 
littermates. in light of available in vitro data (Liao et al., 2005), 
one plausible explanation would be that chronic morphine 
exposure during this early phase of synaptogenesis would 
impede the stabilization of newly formed spines and that this 
would lead to an increased turnover and thus a higher percentage 
of immature spine in this experimental group. Further studies 
will be required to shed light on this issue.
The clinical relevance of our observations remains to be 
established. To our belief, we provide here the first in vivo 
study regarding the effects of morphine exposure during the 
brain growth spurt. According to works on extrapolating 
brain development from experimental species to humans, the 
developmental period situated between the first and third weeks 
of postnatal life in rat pups corresponds to a period extending 
from the third trimester of pregnancy up to the first few years of 
life in humans (clancy et al., 2001, 2007). We thus consider that 
experiments conducted around PND 7 would have preclinical 
relevance regarding morphine exposure to premature children, 
whereas drug exposure in PND 15 animals might reflect a 
developmental stage somewhere during the first few years of 
life in humans. Extrapolation of experimental results is further 
complicated by the fact that even a single dose–induced few-
hour-long effect might reflect exposure to weeks or months in 
the human time scale (Anand and soriano, 2004). Nevertheless, 
given the lack of any morphological effects that might suggest 
neurotoxicity of morphine in our experimental paradigms, we 
believe that our results bring preclinical arguments in favor of 
the relative safety of this drug during the brain growth spurt. 
These results are of particular interest in view of the large 
amount of data suggesting that exposure to the majority of 
general anesthetics rapidly induces experimental neurotoxicity 
during this developmental period (Loepke and soriano, 2008). 
To our knowledge, and despite the fact that opioids constitute 
one of the main pharmacological approaches to alleviate pain in 
neonates (Anand, 2001) and in children (Duedahl and Hansen, 
2007; Tesler et al., 1994), there are sparse data on long-term 
neurocognitive and behavioral effects of neonatal morphine 
exposure. Morphine administration in very premature neonates 
FIG. 8. Repeated daily administration of morphine during the later phase of the brain growth spurt does not affect dendritic spine density and morphology. 
(A) Experimental protocol. (B) Representative volume rendering confocal reconstructions of dendritic shafts from control and morphine-exposed animals. (c) 
Quantitative analysis of dendritic spine densities on second-order basal dendritic shafts. (D) Frequency distribution histogram of spine head diameters in control 
and morphine-treated groups. Data are expressed as mean ± sD, n = 3 animals at each drug regimen. One-way ANOVA with Bonferroni’s post hoc tests was used 
for searching statistical differences between experimental conditions. A total of 4802 spines for controls, 7147 spines for the 1 mg/kg morphine group, and 5442 
spines for the 10 mg/kg morphine group were counted to determine spine density. scale bar: 4 μm.
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did not seem to have any adverse effects on intelligence, motor 
function, or behavior when these children are assessed at 
5–6 years of age (MacGregor et al., 1998). A recent follow-up 
study among 5-year-old children who have previously been 
involved in a placebo-controlled trial on the effects of morphine 
on pain and neurologic outcome demonstrated significantly 
lower overall intelligence quotient score compared with 
the placebo group; these differences, however, disappeared 
following correction for potential confounding factors (de 
Graaf et  al., 2011). Nevertheless, scores on one iQ subtest, 
“visual analysis,” were significantly negatively related to 
having received morphine, warranting longer term follow-up 
in these children by focusing on higher order neurocognitive 
function (de Graaf et al., 2011).
in conclusion, this study demonstrates that morphine expos-
ure during the most intense period of neuronal differentiation 
and synaptogenesis does not induce apoptosis in the mPFc, 
a cortical region of utmost importance in mediating higher 
order cognitive functions. importantly, this drug did not affect 
dendritic differentiation of layer 5 pyramidal neurons in this 
cortical region and had no impact on dendritic spine dens-
ities of these cells. These experimental observations, in line 
and together with recent preclinical data (Black et al., 2008; 
Emeterio et al., 2006; Rizzi et al., 2008; Westin et al., 2010), 
suggest the lack of overt neurotoxic effects of this drug during 
the brain growth spurt.
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